Evidence map›Paper›PMID 28183299›Full record

ArticleMalaria journal2017

Avidity of anti-malarial antibodies inversely related to transmission intensity at three sites in Uganda.

Isaac Ssewanyana, Emmanuel Arinaitwe, Joaniter I Nankabirwa, Adoke Yeka, Richard Sullivan, Moses R Kamya, Philip J Rosenthal, Grant Dorsey, Harriet Mayanja-Kizza, Chris Drakeley and 2 more

Open access · goldAbstract read
In one paragraph

Article in Malaria journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 35 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Review
  5. Article
  6. Natural killer cell antibody-dependent cellular cytotoxicity toClinical & translational immunology · 2024
    Article
  7. Article
  8. Article
  9. Host-parasite interactions duringFrontiers in immunology · 2022
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Isaac SsewanyanaInfectious Diseases Research Collaboration, Kampala, Uganda. sewyisaac@yahoo.co.uk.ORCID 0000-0001-8605-2001
Emmanuel ArinaitweInfectious Diseases Research Collaboration, Kampala, Uganda.
Joaniter I NankabirwaInfectious Diseases Research Collaboration, Kampala, Uganda.
Adoke YekaInfectious Diseases Research Collaboration, Kampala, Uganda.
Richard SullivanDepartment of Medicine, San Francisco General Hospital, University of California, San Francisco, CA, USA.
Moses R KamyaInfectious Diseases Research Collaboration, Kampala, Uganda.
Philip J RosenthalDepartment of Medicine, San Francisco General Hospital, University of California, San Francisco, CA, USA.
Grant DorseyDepartment of Medicine, San Francisco General Hospital, University of California, San Francisco, CA, USA.
Harriet Mayanja-KizzaDepartment of Medicine, Makerere University College of Health Sciences, Kampala, Uganda.
Chris DrakeleyLondon School of Hygiene and Tropical Medicine, London, UK.
Bryan GreenhouseDepartment of Medicine, San Francisco General Hospital, University of California, San Francisco, CA, USA.
Kevin K A TettehLondon School of Hygiene and Tropical Medicine, London, UK.
London School of Hygiene & Tropical Medicine · GBSan Francisco General Hospital · USInfectious Diseases Research Collaboration · UGMakerere University · UG

Funding

Transmission ProjectU19AI089674 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MATTHEW G DORSEY, MOSES Robert KAMYA · 2010 to 2026
$29.3M
Training In Malaria Research in UgandaD43TW007375 · FIC · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENTHAL, PHILIP JON · 2005 to 2019
$2.9M
FIC NIH HHS D43 TW007375NIAID NIH HHS U19 AI089674
6 · The paper itself

Abstract

backgroundPeople living in malaria endemic areas acquire protection from severe malaria quickly, but protection from clinical disease and control of parasitaemia is acquired only after many years of repeated infections. Antibodies play a central role in protection from clinical disease; however, protective antibodies are slow to develop. This study sought to investigate the influence of Plasmodium falciparum exposure on the acquisition of high-avidity antibodies to P. falciparum antigens, which may be associated with protection.

methodsCross-sectional surveys were performed in children and adults at three sites in Uganda with varied P. falciparum transmission intensity (entomological inoculation rates; 3.8, 26.6, and 125 infectious bites per person per year). Sandwich ELISA was used to measure antibody responses to two P. falciparum merozoite surface antigens: merozoite surface protein 1-19 (MSP1-19) and apical membrane antigen 1 (AMA1). In individuals with detectable antibody levels, guanidine hydrochloride (GuHCl) was added to measure the relative avidity of antibody responses by ELISA.

resultsWithin a site, there were no significant differences in median antibody levels between the three age groups. Between sites, median antibody levels were generally higher in the higher transmission sites, with differences more apparent for AMA-1 and in ≥5 year group. Similarly, median avidity index (proportion of high avidity antibodies) showed no significant increase with increasing age but was significantly lower at sites of higher transmission amongst participants ≥5 years of age. Using 5 M GuHCl, the median avidity indices in the ≥5 year group at the highest and lowest transmission sites were 19.9 and 26.8, respectively (p = 0.0002) for MSP1-19 and 12.2 and 17.2 (p = 0.0007) for AMA1.

conclusionAvidity to two different P. falciparum antigens was lower in areas of high transmission intensity compared to areas with lower transmission. Appreciation of the mechanisms behind these findings as well as their clinical consequences will require additional investigation, ideally utilizing longitudinal data and investigation of a broader array of responses.

Indexed as

Antibody AffinityAdolescentAdultAgedAged, 80 and overAntibodies, ProtozoanChildChild, PreschoolCross-Sectional StudiesEnzyme-Linked Immunosorbent AssayFemaleHumansInfantMalaria, FalciparumMaleMerozoitesAntibodies, ProtozoanAntibodyAvidityMalariaPlasmodium falciparumTransmissionUganda

Identifiers

PMID28183299
PMCPMC5301436
OpenAlexW2586446632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.